Episode
Viking Therapeutics Weight Loss Drug Update | Business and Finance News
- Published
- Jul 18, 2026
- Duration seconds
- 83
- Processing state
not_requested- Canonical source
- https://sources.thednn.ai/31dea84f4ea0652c
Actions
POST https://stenobird.com/v1/public/podcasts/business-finance-news-today-2-min-news-the-daily-news-now-7726192/episodes/viking-therapeutics-weight-loss-drug-update-business-and-finance-news/transcription-requests
Idempotently request low-priority transcript generation for this episode.GET https://stenobird.com/podcast/business-finance-news-today-2-min-news-the-daily-news-now-7726192/viking-therapeutics-weight-loss-drug-update-business-and-finance-news.md
Read the agent-friendly Markdown representation of this episode resource.
Summary
Viking Therapeutics is heating up with its weight-loss drug VK2735, showing faster results than rivals and sparking Wall Street excitement after a recent stock surge. The injectable version is already in trials, while the pill form launches later this year—with phase three data expected by late 2027 for the shot and 2028 for the tablet. Early maintenance results may come this quarter, but investors should tread carefully: tolerance questions linger, and big confirmations are still years away. High potential, but patience is key. Listen in comfort: Get a discount on a Soli Pillow: http://solipillow.com/discount/dnn. Advertise on DNN: [email protected] This is an automated, high-level news summary based on public reporting. Report issues to [email protected]. View sources & latest updates: https://sources.thednn.ai/31dea84f4ea0652c